In vivo experiments showed that both prophylactic and therapeutic schemes of DC vaccination were efficient in tumor growth retardation in MC38/MUC1 colon cancer, LLC, EL4 thymoma and HPV16-associated MK16 tumor models [30, 31, 36, 37], whereas WEHI-164 fibrosarcoma and MC38/CEA colon cancer were more sensitive to prophylactic DC vaccines with low if any antitumor efficiency of therapeutic scheme of DC vaccination [34, 35]. This evidence concerns the gene MUC1 and malignant colon neoplasm.